Сравнение

Carbetocin vs. Cerebrolysin

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

37025-55-1

96889-70-6

Молекулярная масса

нет данных

Период полувыведения

0.67 h

нет данных

Последовательность

нет данных

Механизм действия

Carbetocin

Carbetocin is an oxytocin receptor agonist with prolonged duration. It triggers a sustained contraction of the uterus after birth, preventing atonic hemorrhage — unlike oxytocin, without a multi-hour infusion.

Cerebrolysin

Cerebrolysin is a mixture of low-molecular-weight peptides (predominantly below 10 kDa) and free amino acids obtained by enzymatic cleavage of lipid-free porcine brain proteins. The manufacturer and preclinical literature describe a neurotrophic and neuroprotective mode of action said to mimic endogenous neurotrophic factors; cell and animal models have reported effects on neuronal survival, synaptogenesis and anti-apoptotic signalling (including PI3K/Akt). Because it is a complex, incompletely characterised mixture, the precise mechanism in humans remains unclear.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Carbetocin	Cerebrolysin
Австрия	—	Рецептурный
CN	—	Рецептурный
Германия	Рецептурный	Неясно
RU	—	Рецептурный
США	Не одобрено	Не одобрено

Полные записи

Frequently asked questions

What is the difference between Carbetocin and Cerebrolysin?: Carbetocin is classified as "Исследования (прочее)", while Cerebrolysin is classified as "Исследования (прочее)". Carbetocin: Carbetocin is a long-acting synthetic oxytocin analog (half-life ~40 minutes). It prevents postpartum hemorrhage as a single injection. Approved in Canada and the UK among others, NOT in the US. Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Carbetocin or Cerebrolysin?: The highest available evidence level is "РКИ на людях" for Carbetocin and "РКИ на людях" for Cerebrolysin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Carbetocin and Cerebrolysin in Germany and the United States?: Германия: Carbetocin — Рецептурный, Cerebrolysin — Неясно. США: Carbetocin — Не одобрено, Cerebrolysin — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

Carbetocin

Cerebrolysin

Австрия

—

Рецептурный

—

Рецептурный

Германия

Рецептурный

Неясно

—

Рецептурный

США

Не одобрено

Frequently asked questions

What is the difference between Carbetocin and Cerebrolysin?

Carbetocin is classified as "Исследования (прочее)", while Cerebrolysin is classified as "Исследования (прочее)". Carbetocin: Carbetocin is a long-acting synthetic oxytocin analog (half-life ~40 minutes). It prevents postpartum hemorrhage as a single injection. Approved in Canada and the UK among others, NOT in the US. Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Carbetocin or Cerebrolysin?

The highest available evidence level is "РКИ на людях" for Carbetocin and "РКИ на людях" for Cerebrolysin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Carbetocin and Cerebrolysin in Germany and the United States?

Германия: Carbetocin — Рецептурный, Cerebrolysin — Неясно. США: Carbetocin — Не одобрено, Cerebrolysin — Не одобрено. These are factual summaries with source and review date on the individual pages.